Helix BioPharma Corp. HBPCF
0.77 USD 0.00 (+0.00%)
At closeNov 13, 2026, 4:00 PM EST
1.71 Day range 1.71
0.77 52-week range 1.73
- YTD
- -55.49%
- 1 year
- -55.49%
News
thenewswire.com Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development Vancouver, British Columbia – TheNewswire - August 17, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPC F ” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology…
thenewswire.com Helix Biopharma Corp. Announces Board Composition Changes Vancouver, British Columbia; August 14, 2026 – TheNewswire - Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology…
thenewswire.com Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development Vancouver, British Columbia – TheNewswire - June 30 , 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology…
thenewswire.com Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026 Vancouver, British Columbia – TheNewswire - June 12, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company…
thenewswire.com Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures Vancouver, British Columbia – TheNewswire - 3 June, 2026 – Helix BioPharma Corp. (TSX: “ HBP ”, OTC PINK: “ HBPCF ”, FRANKFURT: “ HBP0 ”) (“ Helix ” or the “ Company ”), a clinical-stage oncology…
thenewswire.com Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options Toronto, Ontario – TheNewswire - May 22, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a…
thenewswire.com Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy Toronto, Ontario – TheNewswire - 13 May, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a…
thenewswire.com Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026 Toronto, Ontario – TheNewswire - 16 March, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a…
thenewswire.com Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London Toronto, Ontario – TheNewswire - February 24, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company…
thenewswire.com Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases (Toronto, Ontario; February 5, 2026) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company…
thenewswire.com Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting Toronto, Ontario – TheNewswire - 30 January, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC: “HBPCF” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a…
thenewswire.com Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025 Toronto, Ontario – TheNewswire - 15 December, 2025 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company…
thenewswire.com Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results Toronto, Ontario – TheNewswire - 29 October 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near…
thenewswire.com Helix BioPharma Responds to Market Activity Toronto, Ontario – TheNewswire - 6 October 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near…
thenewswire.com Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025 Toronto, Ontario – TheNewswire - 9 September 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near…
accessnewswire.com Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025 TORONTO, ON / ACCESS Newswire / September 9, 2025 / Helix BioPharma Corp. (TSX:HBP)(OTC:HBPCF)(FRANKFURT:HBP0) ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future…
thenewswire.com Helix BioPharma Concludes Review, Will Not Proceed with Proposed Equity Draw-Down Subscription Facility with GEM Toronto, Ontario – TheNewswire - 5 September 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near…
thenewswire.com Helix Biopharma Corp. Announces Closing of Private Placement, in Preparation for Institutional Investment and NASDAQ Uplisting Toronto, Ontario (22 August 2025) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near…
thenewswire.com Helix Biopharma Corp. Announces Publication in Frontiers in Oncology on the Effects of L-DOS47 as Monotherapy in NSCLC Toronto, Ontario – TheNewswire - 13 August 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a…
thenewswire.com Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Nine Month Period Ended April 30, 2025 (Toronto, Ontario) – Helix BioPharma Corp. - TheNewswire - (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future…
benzinga.com Stocks That Hit 52-Week Highs On Friday